Abstract 829
Background
there is little solid evidence of the effectiveness of psychological interventions using MBRS program for those with advanced cancer. The objective of this study was to evaluate the acceptability and potential benefits of MBSR for pt with cancer pain in early palliative care.
Methods
Main inclusion criteria were: advanced cancer pt in early palliative care; NRS >3;PS >60% according to Karnosky, informed consent. 20 advanced cancer pt were enrolled. Each session included different forms of mindfulness meditation practice, mindful awareness during yoga postures and mindfulness during stressful situations. Participants enter upon enrolling into a commitment to carry out daily 45-min homework assignments .A dedicate nurse with experience in palliative care attended each mindfulness session. Primary outcome was total pain at the end of MBSR intervention evaluated by both VAS and ESAS scales. Secondary outcome was mood state change evaluated by POMS questionnaire. Satisfaction of treatment and compliance were also evaluated. All questionnaires along with a form for collecting personal and clinical data were administered by nurse at baseline and at the end of MBSR intervention.
Results
19 out of 20 were female with median age 54 years old. 56% were receiving morphine for cancer pain. Preliminary results did show slight reduction in total pain score which however was not statistically significant. The POMS test showed significant changes in the mean scores indicating a statistically significant improvement of mood at the end of mindfulness sessions. Compliance program and homework was 70% while pt satisfaction was 78%.
Conclusions
This program appears to be feasible and well accepted. The improvements in the mood state suggests that the mindfulness techniques could play a role in helping patients to reduce mood disturbance. The role of nurse was optimal to allow critically ill patients to participate in MBRS and to guarantee adherence and satisfaction. Moreover nurse was very helful to support the mindfulness trainer in managing cancer patients according to their physical needs. Finally the presence of nurse has been evaluated by patients as part of cancer caring.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabrizio Artioli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract